Other Restructuring

27th August, 2026 (1) BSE Limited (2) National Stock Exchange of India Limited Listing Department, Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th floor, Dalal Street, Plot no. C/1, G Block, Mumbai 400 001 Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Code: 500087 Scrip Code: CIPLA (3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg Sub: Intimation under Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) Dear Sir/Madam, Pursuant to Regulation 30 of the Listing Regulations, we hereby inform you that with a view to rationalise and simplify the group structure, Aspergen Limited, India, a 60:40 joint venture between the Company and Kemwell Biopharma Private Limited, has acquired 100% stake in Aspergen Inc., USA, a step-down subsidiary of the Company, from Cipla (EU) Limited (holding 60% stake), a wholly owned subsidiary of the Company, and Kemwell Biopharma UK Limited (holding 40% stake). Consequently, Aspergen Inc., USA has become a wholly owned subsidiary of Aspergen Limited, India. There is no change in the Company's economic interest in Aspergen Inc., USA pursuant to the aforesaid restructuring. The details required to be disclosed under the Listing Regulations read with SEBI Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026 on the captioned subject are enclosed to this letter. Please take the above information on record. Yours faithfully, For Cipla Limited Rajendra Chopra Company Secretary Prepared by: Simona Dsouza Cipla Ltd. Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India P +91 22 41916000 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380 Annexure - I Details as per SEBI circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026 Sr. Particulars Details a) details and reasons Aspergen Limited, India, a 60:40 joint venture between the Company and Kemwell for restructuring Biopharma Private Limited, has acquired 100% stake in Aspergen Inc., USA, a step-down subsidiary of the Company, from Cipla (EU) Limited (holding 60% stake), a wholly owned subsidiary of the Company, and Kemwell Biopharma UK Limited (holding 40% stake). Consequently, Aspergen Inc., USA has become a b) quantitative and/ or wholly owned subsidiary of Aspergen Limited, India. There is no change in the qualitative effect of Company's economic interest in Aspergen Inc., USA, pursuant to the aforesaid restructuring restructuring. The said restructuring has been undertaken with a view to rationalise and simplify the group structure. c) details of benefit, if Nil any, to the promoter/promoter group / group companies from such proposed restructuring d) brief details of Change in shareholding pattern: change in Pre-restructuring Post-restructuring shareholding pattern Name of Company Name of Stake Name of Stake (if any) of all entities shareholders held shareholders held Cipla Limited 60% Cipla Limited 60% Aspergen Limited, Kemwell India Kemwell Biopharma 40% Biopharma Private 40% Private Limited Limited Cipla (EU) Limited 60% Aspergen Aspergen Limited 100% Inc., USA Kemwell Biopharma UK Limited There is no change in the Company's economic interest in Aspergen Inc., USA, pursuant to the aforesaid restructuring. Cipla Ltd. Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India P +91 22 41916000 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380